Cannabinoids and endocannabinoids as therapeutics for nervous system disorders:preclinical models and clinical studies
作者机构:Department of OphthalmologySchool of MedicineUniversity of Missouri Department of Biomedical SciencesSchool of MedicineUniversity of Missouri
出 版 物:《Neural Regeneration Research》 (中国神经再生研究(英文版))
年 卷 期:2024年第19卷第4期
页 面:788-799页
核心收录:
学科分类:0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100204[医学-神经病学] 10[医学]
基 金:supported in part by grants from the National Institute on Aging and National Eye Institute[EY030747(3R01EY030747-02S2)and EY031248(3R01EY03124802S1)]of the National Institutes of Health(to PK) Additional support by the Felix and Carmen Sabates Missouri Endowed Chair in Vision Research the Vision Research Foundation of Kansas City
主 题:anandamide cannabidiol cannabinoid endocannabinoid epilepsy multiple sclerosis neurodegeneration neuroprotection tetrahydrocannabinol
摘 要:Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human *** have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human *** of these include central nervous system(CNS)diseases and dysfunctions such as forms of epilepsy,multiple sclerosis,Parkinson’s disease,pain and neuropsychiatric *** addition,the endogenously produced cannabinoid lipids,endocannabinoids,are critical for normal CNS function,and if controlled or modified,may represent an additional therapeutic avenue for CNS *** review discusses in vitro cellular,ex vivo tissue and in vivo animal model studies on cannabinoids and their utility as therapeutics in multiple CNS *** addition,the review provides an overview on the use of cannabinoids in human clinical trials for a variety of CNS *** and endocannabinoids hold promise for use as disease modifiers and therapeutic agents for the prevention or treatment of neurodegenerative diseases and neurological disorders.